AHA comments on Medicare Part B Inflation Reduction Act rebate guidance
In comments submitted Saturday, AHA generally supports the Centers for Medicare & Medicaid Services’ initial guidance implementing inflation rebates for certain single source drugs and biosimilar biological products covered by Medicare Part B, but recommends changes to prevent incentivizing drug shortages and burdening 340B hospitals. Drug units purchased under the 340B program are not subject to the Inflation Reduction Act rebates.
Related News Articles
Headline
A blog by Noah Isserman, AHA director of health insurance and coverage policy, explains why a recent analysis by the Medicare Payment Advisory Commission…
Blog
Medicare Advantage now covers more than half of eligible Medicare beneficiaries, making its impact on hospitals, health systems and patients impossible to…
Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services released a proposed rule June 12 seeking to codify the…
Headline
The Medicare Payment Advisory Commission June 15 released its June report to Congress that estimated the association between Medicare Advantage enrollment and…
Headline
The Centers for Medicare & Medicaid Services June 12 issued a final rule revising how the agency conducts oversight of accrediting organizations that…
Headline
The Department of Health and Human Services Office of Inspector General June 11 released two reports on high rates of coverage denials by Medicare Advantage…